Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR
about
Structure-based methods for predicting target mutation-induced drug resistance and rational drug design to overcome the problemIn vitro and in vivo models for analysis of resistance to anticancer molecular therapiesDe Novo Design of Protein Kinase Inhibitors by in Silico Identification of Hinge Region-Binding FragmentsInsight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFRCovalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition ReactionsIn silico identification of EGFR-T790M inhibitors with novel scaffolds: start with extraction of common featuresPartial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC.Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy.Quinazoline derivatives as potential anticancer agents: a patent review (2007 - 2010).Epidermal growth factor receptor inhibitors: a patent review (2010 - present).Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic Approaches, and Clinical Profiles.Recent Development of the Second and Third Generation Irreversible Epidermal Growth Factor Receptor Inhibitors.Synthesis and biological evaluation of p38alpha kinase-targeting dialkynylimidazoles.Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer.Navigating the "No Man's Land" of TKI-Failed EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): A Review.Synthesis and antitumor activity of novel 4-(2-fluorophenoxy)quinoline derivatives bearing the 4-oxo-1,4-dihydroquinoline-3-carboxamide moiety.Epidermal growth factor receptor (EGFR) structure-based bioactive pharmacophore models for identifying next-generation inhibitors against clinically relevant EGFR mutations.Lessons to be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer.Epidermal growth factor receptor somatic mutation analysis in 354 Chinese patients with non-small cell lung cancer.L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib.
P2860
Q26829549-A431D12C-AE78-4E98-9532-F82A729442A6Q27014174-D8CB4EFD-43AD-476A-975F-6935C11FD8C0Q27677088-7BD10426-ED6B-4743-A5DB-BA70F8CB906AQ27725743-5F1F11F9-DA7F-4F07-A6C0-D2C1322450BDQ29248430-3D1CF3FA-059F-483F-8E47-DB15D64D40EDQ34976925-AE7BF4A3-FA8F-4CC6-AE8F-8EAD4641270EQ37019034-10AB0B5E-B437-40D6-A009-5D84E33E3B86Q37564201-CB16EBE5-45C1-4641-84A7-87B435C3FC89Q37992086-AA78D9A7-60D6-42E2-9D0E-CCD6EDF8298AQ38175432-89937747-11C6-43EF-B3FF-DB44C57D0AFEQ38766833-9AA5FB8B-087C-40DE-82E3-744CC7735C23Q39079553-090774B1-23E6-4A39-886F-5048D3B538A0Q42960886-0EE33B2D-690B-4990-8903-001EDC538D31Q43083907-BD4A9757-AD3B-40E1-8B36-A6D0E95872DAQ45973958-C609585C-032A-40EF-BAC8-FD22BED34104Q46492003-17A5E940-924B-43FA-8269-7812E464B7BAQ48044733-B9ECCB91-D7DA-41A5-9FB7-137FA9B814C1Q48231295-26D28502-E448-4DE5-9201-E08F442A77EDQ49468021-FB93C577-4D2C-43A0-A9A4-7976541D0684Q55410133-3DD5BA46-FA8B-4BF5-957C-0445F27ED139
P2860
Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR
@ast
Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR
@en
Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR
@nl
type
label
Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR
@ast
Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR
@en
Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR
@nl
prefLabel
Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR
@ast
Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR
@en
Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR
@nl
P2093
P3181
P1476
Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR
@en
P2093
Christian Grütter
Haridas B Rode
Jeffrey R Simard
Matthias Rabiller
Sabine Klüter
P304
P3181
P356
10.1016/J.BMC.2008.02.053
P407
P577
2008-02-20T00:00:00Z